33806197|t|A Novel Galantamine-Curcumin Hybrid as a Potential Multi-Target Agent against Neurodegenerative Disorders.
33806197|a|The acetylcholinesterase (AChE) inhibitors are the main drugs for symptomatic treatment of neurodegenerative disorders like Alzheimer's disease. A recently designed, synthesized and tested hybrid compound between the AChE inhibitor galantamine (GAL) and the antioxidant polyphenol curcumin (CU) showed high AChE inhibition in vitro. Here, we describe tests for acute and short-term toxicity in mice as well as antioxidant tests on brain homogenates measured the levels of malondialdehide (MDA) and glutathione (GSH) and in vitro DPPH, ABTS, FRAP and LPO inhibition assays. Hematological and serum biochemical analyses were also performed. In the acute toxicity tests, the novel AChE inhibitor given orally in mice showed LD50 of 49 mg/kg. The short-term administration of 2.5 and 5 mg/kg did not show toxicity. In the ex vivo tests, the GAL-CU hybrid performed better than GAL and CU themselves; in a dose of 5 mg/kg, it demonstrates 25% reduction in AChE activity, as well as a 28% and 73% increase in the levels of MDA and GSH, respectively. No significant changes in blood biochemical data were observed. The antioxidant activity of 4b measured ex vivo was proven in the in vitro tests. In the ABTS assay, 4b showed radical scavenging activity 10 times higher than the positive control butylhydroxy toluol (BHT). The GAL-CU hybrid is a novel non-toxic AChE inhibitor with high antioxidant activity which makes it a prospective multitarget drug candidate for treatment of neurodegenerative disorders.
33806197	8	19	Galantamine	Chemical	MESH:D005702
33806197	20	28	Curcumin	Chemical	MESH:D003474
33806197	78	105	Neurodegenerative Disorders	Disease	MESH:D019636
33806197	111	131	acetylcholinesterase	Gene	11423
33806197	133	137	AChE	Gene	11423
33806197	198	225	neurodegenerative disorders	Disease	MESH:D019636
33806197	231	250	Alzheimer's disease	Disease	MESH:D000544
33806197	324	328	AChE	Gene	11423
33806197	339	350	galantamine	Chemical	MESH:D005702
33806197	352	355	GAL	Chemical	MESH:D005702
33806197	388	396	curcumin	Chemical	MESH:D003474
33806197	398	400	CU	Chemical	MESH:D003474
33806197	414	418	AChE	Gene	11423
33806197	489	497	toxicity	Disease	MESH:D064420
33806197	501	505	mice	Species	10090
33806197	579	594	malondialdehide	Chemical	-
33806197	596	599	MDA	Chemical	-
33806197	605	616	glutathione	Chemical	MESH:D005978
33806197	618	621	GSH	Chemical	MESH:D005978
33806197	636	640	DPPH	Chemical	MESH:C004931
33806197	642	646	ABTS	Chemical	MESH:C002502
33806197	657	660	LPO	Chemical	MESH:D008054
33806197	759	767	toxicity	Disease	MESH:D064420
33806197	785	789	AChE	Gene	11423
33806197	816	820	mice	Species	10090
33806197	908	916	toxicity	Disease	MESH:D064420
33806197	944	947	GAL	Chemical	MESH:D005702
33806197	948	950	CU	Chemical	MESH:D003474
33806197	980	983	GAL	Chemical	MESH:D005702
33806197	988	990	CU	Chemical	MESH:D003474
33806197	1058	1062	AChE	Gene	11423
33806197	1124	1127	MDA	Chemical	-
33806197	1132	1135	GSH	Chemical	MESH:D005978
33806197	1243	1245	4b	Chemical	-
33806197	1304	1308	ABTS	Chemical	MESH:C002502
33806197	1316	1318	4b	Chemical	-
33806197	1396	1415	butylhydroxy toluol	Chemical	-
33806197	1417	1420	BHT	Chemical	-
33806197	1427	1430	GAL	Chemical	MESH:D005702
33806197	1431	1433	CU	Chemical	MESH:D003474
33806197	1462	1466	AChE	Gene	11423
33806197	1581	1608	neurodegenerative disorders	Disease	MESH:D019636
33806197	Negative_Correlation	MESH:D005702	MESH:D019636
33806197	Positive_Correlation	MESH:D003474	MESH:D005978
33806197	Positive_Correlation	MESH:D005702	MESH:D005978
33806197	Negative_Correlation	MESH:C004931	MESH:D008054
33806197	Association	MESH:D019636	11423
33806197	Negative_Correlation	MESH:D005702	11423
33806197	Association	MESH:D000544	11423
33806197	Cotreatment	MESH:D003474	MESH:D005702
33806197	Negative_Correlation	MESH:D003474	MESH:D019636
33806197	Negative_Correlation	MESH:D003474	11423

